Neonc Technologies (NASDAQ:NTHI) Stock: Insider Thomas Chen Acquires 2,284 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CMO Thomas Chen acquired 2,284 shares of the stock in a transaction dated Tuesday, November 10th. The stock was bought at an average cost of $4.38 per share, with a total value of $10,003.92. Following the completion of the purchase, the chief marketing officer directly owned 29,519 shares in the company, valued at approximately $129,293.22. The trade was a 8.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Neonc Technologies Price Performance

Shares of Neonc Technologies stock traded up $0.06 on Friday, reaching $4.91. The company had a trading volume of 251,853 shares, compared to its average volume of 118,828. The firm’s 50-day moving average price is $3.30 and its two-hundred day moving average price is $5.27. Neonc Technologies Holdings, Inc. has a 1 year low of $2.50 and a 1 year high of $11.38.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03).

Institutional Investors Weigh In On Neonc Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its position in Neonc Technologies by 5.0% in the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock valued at $1,650,000 after buying an additional 11,108 shares during the period. Westmount Partners LLC raised its stake in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after acquiring an additional 153,858 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Neonc Technologies in the second quarter valued at approximately $815,000. Marshall Wace LLP boosted its holdings in shares of Neonc Technologies by 423.5% in the third quarter. Marshall Wace LLP now owns 114,046 shares of the company’s stock valued at $388,000 after purchasing an additional 92,262 shares during the period. Finally, Global Retirement Partners LLC purchased a new stake in shares of Neonc Technologies in the second quarter valued at approximately $126,000.

Wall Street Analyst Weigh In

NTHI has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Neonc Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Roth Capital began coverage on shares of Neonc Technologies in a report on Thursday, September 24th. They issued a “buy” rating for the company. Weiss Ratings cut shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. BTIG Research reiterated a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, September 8th. Finally, Zacks Research upgraded shares of Neonc Technologies from a “strong sell” rating to a “hold” rating in a report on Thursday, November 5th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Neonc Technologies Company Profile

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.